SOLICITATION NOTICE
Q -- Family Studies Support
- Notice Date
- 8/26/2011
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-110175-LG
- Archive Date
- 9/27/2011
- Point of Contact
- Laura Glockner, Phone: 3014968607
- E-Mail Address
-
laura.glockner@nih.gov
(laura.glockner@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Room 6070, Rockville, MD, 20852, UNITED STATES Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Genetic Epidemiology Branch (GEB) plans to procure on a sole source basis services to coordinate ongoing melanoma patient accrual, family education and follow-up programs of advanced technology-based testing from Mary C. Fraser, R.N., M.A., 15224 Turkey Foot Road, Gaithersburg, MD 20878. The services herein are being procured in accordance with the simplified acquisition procedures as authorized by FAR Part 13.106-1 (b)(1). The North American Industry Classification System code is 541990 and the business size standard is $7.0 million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance shall be for twelve (12) months from date of award. The Genetic Epidemiology Branch (GEB) of the Division of Cancer Epidemiology and Genetics conducts studies to evaluate the interaction of host and environmental factors in cancer causation. A cornerstone of this research is family studies: the interdisciplinary clinical, genetic, epidemiologic and laboratory evaluations of kindreds and individuals with or at high risk of specific cancers or tumors. By expanding the number of kindreds studied with different cancers and following them over several decades, the GEB has been able to demonstrate the presence of genetic heterogeneity in some cancer syndromes, assess the occurrence of genotype-phenotype correlations, define the natural history, quantify prospective risks of cancers in members of some types of families, evaluate gene-gene or gene-environmental interactions, and integrate environmental risk factors into risk analyses. Historically, melanoma is the earliest, the largest, and one of the most important cancer syndrome studied by the Genetic Epidemiology Branch (GEB). Currently, GEB actively studies about 75 families including over 1500 examined family members, and has been prospectively following these families for up to 35 years as the program continues to accrue new families. GEB is very interested in identifying susceptibility gene(s) for dysplastic nevi and additional genes for CMM because GEB scientists played a key role in the identification of dysplastic nevi and identified the first two high risk susceptibility genes. To accomplish this, a program of education followed by requests for informed consent needs to be initiated, administered and tracked. This effort requires a highly experienced, knowledgeable coordinator with intimate knowledge of the families, the individual family members, cancer genetics, the intricacies of pigmented lesions and their recognition, clinical and family evaluation and treatment. GEB requires a nurse specialist with extensive expertise in studies of familial melanoma to lead and coordinate the efforts to accrue new melanoma families, to consent participants from existing families for posting of results from exomic/complete genomics sequencing, and to oversee the complex process for returning mutation testing results to subjects from families with an identified mutation. Mary C. Fraser is a nurse specialist who provides support for high quality clinical and genetic studies of patients and families at increased risk for cancer. Over the past 25 years she coordinated genetic research directed at pigmented lesions and the precursor states that predispose to cancer. Her role in these studies included identifying patients and families of interest, obtaining and interpreting individual and family medical histories, delineating and arranging appropriate diagnostic studies, conducting detailed skin exams, the procurement of research specimens, directing and participating in the clinical evaluation of family members, providing genetic counseling to affected and at risk family members, coordinating clinics involving clinicians, geneticists, and nurses, counseling patients and families and designing, preparing and distributing electronic and web-based as well as printed educational materials. Over this period Mary Fraser played a critical role in support of the Branch's familial melanoma effort, involving the study of over 75 high risk families including clinical examination of over 1,500 individuals. These studies have led to the identification of melanoma susceptibility genes and the characterization of the precursor condition, dysplastic nevus syndrome (DNS), and delineated the spectrum of clinical manifestations associated with the precursor condition. Mary C. Fraser's in-depth knowledge of clinical aspects of familial and sporadic melanoma and dysplastic nevus syndrome are unique assets that no other contractor can provide. She has been credentialed as a clinician by the NIH Clinical Center in the past and understands the process from the clinical perspective. Accordingly, there is no other health professional with the experience, expertise and detailed knowledge of these studies to perform the tasks covered by this procurement. This notice is not a request for a competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 11:00 AM EST, on September 12, 2011. For further information, please contact Laura Glockner, Contract Specialist via electronic mail at laura.glockner@nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Reference: NCI-110175-LG on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-110175-LG/listing.html)
- Record
- SN02552179-W 20110828/110827000326-e7e99514de3896431cb3925db6812f1b (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |